SLC7A11 is closely related to tumor growth, prognosis, metastasis, and treatment of malignant tumors, and its high expression is an unfavorable factor for the disease-specific survival rate of eight types of tumors, including prostate cancer, adrenocortical carcinoma, bladder cancer, and squamous cell carcinoma of the head and neck [36]. Here, SLC7A11 is linked to urinary bladder cancer.